Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Angiogenesis [[electronic resource] ] : an integrative approach from science to medicine / / edited by William D. Figg, Judah Folkman
| Angiogenesis [[electronic resource] ] : an integrative approach from science to medicine / / edited by William D. Figg, Judah Folkman |
| Edizione | [1st ed. 2008.] |
| Pubbl/distr/stampa | New York, NY, : Springer, c2008 |
| Descrizione fisica | 1 online resource (616 p.) |
| Disciplina | 612.13 |
| Altri autori (Persone) |
FiggWilliam D
FolkmanM. Judah |
| Soggetto topico |
Neovascularization
Blood - Circulation |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-281-37805-4
9786611378059 0-387-71518-5 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Physiological & Pathological Angiogenesis: Biology of the Angiogenic Process -- History of Angiogenesis -- Angiogenesis and Vascular Remodeling in Inflammation and Cancer: Biology and Architecture of the Vasculature -- Endothelial Cell Activation -- Pericytes, the Mural Cells of the Microvascular System -- Matrix Metalloproteinases and Their Endogenous Inhibitors -- Integrins in Angiogenesis -- Angiogenesis and Regulatory Proteins -- Fibroblast Growth Factor-2 in Angiogenesis -- Vascular Permeability/Vascular Endothelial Growth Factor -- Platelet-Derived Growth Factor -- Angiopoietins and Tie Receptors -- Basement Membrane Derived Inhibitors of Angiogenesis -- Angiostatin and Endostatin: Angiogenesis Inhibitors in Blood and Stroma -- Thrombospondins: Endogenous Inhibitors of Angiogenesis -- Molecular & Cellular Mechanisms of the Angiogenic Process -- Overview of Angiogenesis During Tumor Growth -- Hypoxic Regulation of Angiogenesis by HIF-1 -- Regulation of Angiogenesis by von Hippel Lindau Protein and HIF2 -- Nitric Oxide in Tumor Angiogenesis -- VEGF Signal Tranduction in Angiogenesis -- Delta-like Ligand 4/Notch Pathway in Tumor Angiogenesis -- Immune Cells and Inflammatory Mediators as Regulators of Tumor Angiogenesis -- Contribution of Endothelial Progenitor Cells to the Angiogenic Process -- Tumor Angiogenesis and the Cancer Stem Cell Model -- Targeting the Tumor Microenvironment (Stroma) for Treatment of Metastasis -- Functional Assessments of Angiogenesis -- Normalization of Tumor Vasculature and Microenvironment -- Targeted Drug Delivery to the Tumor Neovasculature -- Models for Angiogenesis -- Surrogates for Clinical Development -- Imaging of Angiogenesis -- Tumor Endothelial Markers -- Clinical Translation of Angiogenesis Inhibitors -- Overview and Clinical Applications of VEGF-A -- Protein Tyrosine Kinase Inhibitors as Antiangiogenic Agents -- Therapeutic Strategies that Target the HIF System -- The Clinical Utility of Bevacizumab -- Development of Thalidomide and Its IMiD Derivatives -- TNP-470: The Resurrection of the First Synthetic Angiogenesis Inhibitor -- Clinical Development of VEGF Trap -- Recent Advances in Angiogenesis Drug Development -- Combination of Antiangiogenic Therapy with Other Anticancer Therapies -- Immunotherapy of Angiogenesis with DNA Vaccines -- Challenges of Antiangiogenic Therapy of Tumors -- Pharmacogenetics of Antiangiogenic Therapy -- Angiogenesis in Health & Disease -- Angiogenesis in the Central Nervous System -- Lymphatic Vascular System and Lymphangiogenesis -- Ocular Neovascularization -- Angiogenesis and Pathology in the Oral Cavity -- Revascularization of Wounds: The Oxygen-Hypoxia Paradox -- Journeys in Coronary Angiogenesis -- Perspectives on the Future of Angiogenesis Research. |
| Record Nr. | UNINA-9910451270903321 |
| New York, NY, : Springer, c2008 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Angiogenesis [[electronic resource] ] : an integrative approach from science to medicine / / edited by William D. Figg, Judah Folkman
| Angiogenesis [[electronic resource] ] : an integrative approach from science to medicine / / edited by William D. Figg, Judah Folkman |
| Edizione | [1st ed. 2008.] |
| Pubbl/distr/stampa | New York, NY, : Springer, c2008 |
| Descrizione fisica | 1 online resource (616 p.) |
| Disciplina | 612.13 |
| Altri autori (Persone) |
FiggWilliam D
FolkmanM. Judah |
| Soggetto topico |
Neovascularization
Blood - Circulation |
| ISBN |
1-281-37805-4
9786611378059 0-387-71518-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Physiological & Pathological Angiogenesis: Biology of the Angiogenic Process -- History of Angiogenesis -- Angiogenesis and Vascular Remodeling in Inflammation and Cancer: Biology and Architecture of the Vasculature -- Endothelial Cell Activation -- Pericytes, the Mural Cells of the Microvascular System -- Matrix Metalloproteinases and Their Endogenous Inhibitors -- Integrins in Angiogenesis -- Angiogenesis and Regulatory Proteins -- Fibroblast Growth Factor-2 in Angiogenesis -- Vascular Permeability/Vascular Endothelial Growth Factor -- Platelet-Derived Growth Factor -- Angiopoietins and Tie Receptors -- Basement Membrane Derived Inhibitors of Angiogenesis -- Angiostatin and Endostatin: Angiogenesis Inhibitors in Blood and Stroma -- Thrombospondins: Endogenous Inhibitors of Angiogenesis -- Molecular & Cellular Mechanisms of the Angiogenic Process -- Overview of Angiogenesis During Tumor Growth -- Hypoxic Regulation of Angiogenesis by HIF-1 -- Regulation of Angiogenesis by von Hippel Lindau Protein and HIF2 -- Nitric Oxide in Tumor Angiogenesis -- VEGF Signal Tranduction in Angiogenesis -- Delta-like Ligand 4/Notch Pathway in Tumor Angiogenesis -- Immune Cells and Inflammatory Mediators as Regulators of Tumor Angiogenesis -- Contribution of Endothelial Progenitor Cells to the Angiogenic Process -- Tumor Angiogenesis and the Cancer Stem Cell Model -- Targeting the Tumor Microenvironment (Stroma) for Treatment of Metastasis -- Functional Assessments of Angiogenesis -- Normalization of Tumor Vasculature and Microenvironment -- Targeted Drug Delivery to the Tumor Neovasculature -- Models for Angiogenesis -- Surrogates for Clinical Development -- Imaging of Angiogenesis -- Tumor Endothelial Markers -- Clinical Translation of Angiogenesis Inhibitors -- Overview and Clinical Applications of VEGF-A -- Protein Tyrosine Kinase Inhibitors as Antiangiogenic Agents -- Therapeutic Strategies that Target the HIF System -- The Clinical Utility of Bevacizumab -- Development of Thalidomide and Its IMiD Derivatives -- TNP-470: The Resurrection of the First Synthetic Angiogenesis Inhibitor -- Clinical Development of VEGF Trap -- Recent Advances in Angiogenesis Drug Development -- Combination of Antiangiogenic Therapy with Other Anticancer Therapies -- Immunotherapy of Angiogenesis with DNA Vaccines -- Challenges of Antiangiogenic Therapy of Tumors -- Pharmacogenetics of Antiangiogenic Therapy -- Angiogenesis in Health & Disease -- Angiogenesis in the Central Nervous System -- Lymphatic Vascular System and Lymphangiogenesis -- Ocular Neovascularization -- Angiogenesis and Pathology in the Oral Cavity -- Revascularization of Wounds: The Oxygen-Hypoxia Paradox -- Journeys in Coronary Angiogenesis -- Perspectives on the Future of Angiogenesis Research. |
| Record Nr. | UNINA-9910777457503321 |
| New York, NY, : Springer, c2008 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Angiogenesis : an integrative approach from science to medicine / / edited by William D. Figg, Judah Folkman
| Angiogenesis : an integrative approach from science to medicine / / edited by William D. Figg, Judah Folkman |
| Edizione | [1st ed. 2008.] |
| Pubbl/distr/stampa | New York, NY, : Springer, c2008 |
| Descrizione fisica | 1 online resource (616 p.) |
| Disciplina | 612.13 |
| Altri autori (Persone) |
FiggWilliam D
FolkmanM. Judah |
| Soggetto topico |
Neovascularization
Blood - Circulation |
| ISBN |
1-281-37805-4
9786611378059 0-387-71518-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Physiological & Pathological Angiogenesis: Biology of the Angiogenic Process -- History of Angiogenesis -- Angiogenesis and Vascular Remodeling in Inflammation and Cancer: Biology and Architecture of the Vasculature -- Endothelial Cell Activation -- Pericytes, the Mural Cells of the Microvascular System -- Matrix Metalloproteinases and Their Endogenous Inhibitors -- Integrins in Angiogenesis -- Angiogenesis and Regulatory Proteins -- Fibroblast Growth Factor-2 in Angiogenesis -- Vascular Permeability/Vascular Endothelial Growth Factor -- Platelet-Derived Growth Factor -- Angiopoietins and Tie Receptors -- Basement Membrane Derived Inhibitors of Angiogenesis -- Angiostatin and Endostatin: Angiogenesis Inhibitors in Blood and Stroma -- Thrombospondins: Endogenous Inhibitors of Angiogenesis -- Molecular & Cellular Mechanisms of the Angiogenic Process -- Overview of Angiogenesis During Tumor Growth -- Hypoxic Regulation of Angiogenesis by HIF-1 -- Regulation of Angiogenesis by von Hippel Lindau Protein and HIF2 -- Nitric Oxide in Tumor Angiogenesis -- VEGF Signal Tranduction in Angiogenesis -- Delta-like Ligand 4/Notch Pathway in Tumor Angiogenesis -- Immune Cells and Inflammatory Mediators as Regulators of Tumor Angiogenesis -- Contribution of Endothelial Progenitor Cells to the Angiogenic Process -- Tumor Angiogenesis and the Cancer Stem Cell Model -- Targeting the Tumor Microenvironment (Stroma) for Treatment of Metastasis -- Functional Assessments of Angiogenesis -- Normalization of Tumor Vasculature and Microenvironment -- Targeted Drug Delivery to the Tumor Neovasculature -- Models for Angiogenesis -- Surrogates for Clinical Development -- Imaging of Angiogenesis -- Tumor Endothelial Markers -- Clinical Translation of Angiogenesis Inhibitors -- Overview and Clinical Applications of VEGF-A -- Protein Tyrosine Kinase Inhibitors as Antiangiogenic Agents -- Therapeutic Strategies that Target the HIF System -- The Clinical Utility of Bevacizumab -- Development of Thalidomide and Its IMiD Derivatives -- TNP-470: The Resurrection of the First Synthetic Angiogenesis Inhibitor -- Clinical Development of VEGF Trap -- Recent Advances in Angiogenesis Drug Development -- Combination of Antiangiogenic Therapy with Other Anticancer Therapies -- Immunotherapy of Angiogenesis with DNA Vaccines -- Challenges of Antiangiogenic Therapy of Tumors -- Pharmacogenetics of Antiangiogenic Therapy -- Angiogenesis in Health & Disease -- Angiogenesis in the Central Nervous System -- Lymphatic Vascular System and Lymphangiogenesis -- Ocular Neovascularization -- Angiogenesis and Pathology in the Oral Cavity -- Revascularization of Wounds: The Oxygen-Hypoxia Paradox -- Journeys in Coronary Angiogenesis -- Perspectives on the Future of Angiogenesis Research. |
| Record Nr. | UNINA-9910824532003321 |
| New York, NY, : Springer, c2008 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Handbook of Anticancer Pharmacokinetics and Pharmacodynamics / / edited by Michelle A. Rudek, Cindy H. Chau, William D. Figg, Howard L. McLeod
| Handbook of Anticancer Pharmacokinetics and Pharmacodynamics / / edited by Michelle A. Rudek, Cindy H. Chau, William D. Figg, Howard L. McLeod |
| Edizione | [2nd ed. 2014.] |
| Pubbl/distr/stampa | New York, NY : , : Springer New York : , : Imprint : Humana, , 2014 |
| Descrizione fisica | 1 online resource (828 p.) |
| Disciplina | 616.994061 |
| Collana | Cancer Drug Discovery and Development |
| Soggetto topico | Pharmacy |
| ISBN | 1-4614-9135-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | 1. Molecular Targets -- 2. Preclinical Screening for New Anticancer Agents -- 3. Natural Product Screening -- 4. Defining the Starting Dose: Should it be mg/kg, mg/m2 or Fixed? -- 5. Phase 0 Trials in Oncology -- 6. Phase I Trials in Oncology - Design and Endpoints -- 7. Quantitative Analytical Methods: Development and Clinical Considerations -- 8. Validation and Control of Bioanalytical Methods -- 9. Anti-Cancer Clinical Pharmacology Overview -- 10. Pharmacokinetic Modeling -- 11. Pharmacometrics -- 12. Pharmacodynamic Modeling -- 13. Protein Binding -- 14. Metabolism (Non-CyP Enzymes) -- 15. Pharmacogenomics and Cancer Therapy: Somatic and Germline Polymorphisms -- 16. Cytochrome P450 -- 17. Polymorphisms in Genes of Drug Targets and Metabolism -- 18. DNA Repair: ERCC1, Nucleotide Excision Repair, and Platinum Resistance -- 19. Drug Interactions -- 20. ABC Transporters: Involvement in Multidrug Resistance and Drug Disposition -- 21. Solute carriers -- 22. High Throughput Platforms in Drug Metabolism and Transport Pharmacogenetics -- 23. Intrathecal Administration -- 24. Microdialysis -- 25. Regional Drug Delivery for Inoperable Pulmonary Malignancies -- 26. Blood-Brain-Barrier & CNS Malignancy -- 27. Radiation and Altering Clinical Pharmacology -- 28. Therapeutic Cancer Vaccines: An Emerging Approach to Cancer Treatment -- 29. Recombinant Immunotoxins -- 30. Monoclonal Antibodies -- 31. Clinical Pharmacology in Pediatrics -- 32. Clinical Pharmacology in the Elderly -- 33. Organ Dysfunction Trials: Background, Historical Barriers, Progress in Overcoming Barriers and Suggestions for Future Trials -- 34. Drug Formulations: How this Affects Anticancer Drug Pharmacokinetics and Pharmacodynamics -- 35. Nanotechnology in Cancer -- 36. Imaging in Drug Development -- 37. Exposure-Response Relationship of Anticancer Agents: Application in Drug Development and Drug Label -- 38. The Role of Phase III Trials in Modern Drug Development -- 39. Clinical Trial Designs for Approval of New Anticancer Agents -- 40. Clinical Pharmacogenetics. |
| Record Nr. | UNINA-9910300086203321 |
| New York, NY : , : Springer New York : , : Imprint : Humana, , 2014 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||